{
    "2021-07-01": [
        [
            {
                "time": "2021-06-01",
                "original_text": "RPT-After early COVID-19 response, Australia stuck in vaccine slow lane",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "vaccine",
                        "slow lane"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2021-07-05",
                "original_text": "Delta variant sparks concerns, future mutations remain a threat",
                "features": {
                    "keywords": [
                        "Delta variant",
                        "concerns",
                        "mutations",
                        "threat"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2021-06-14",
                "original_text": "Why Spero Therapeutics Stock Is Up 15% Today",
                "features": {
                    "keywords": [
                        "Spero Therapeutics",
                        "Stock",
                        "Up",
                        "15%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-23",
                "original_text": "Is Pfizer Stock A Buy Or Sell As Officials Examine Vaccine-Linked Heart Condition?",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Stock",
                        "Buy",
                        "Sell",
                        "Vaccine-Linked",
                        "Heart Condition"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-07-01",
                "original_text": "3 Big Drugmakers Likely to be in Focus in Second Half of 2021",
                "features": {
                    "keywords": [
                        "Drugmakers",
                        "Focus",
                        "Second Half",
                        "2021"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-28",
                "original_text": "The Zacks Analyst Blog Highlights: Pfizer, Qualcomm, Philip Morris International, Freeport-McMoRan and FedEx",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst",
                        "Blog",
                        "Pfizer",
                        "Qualcomm",
                        "Philip Morris International",
                        "Freeport-McMoRan",
                        "FedEx"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "technology",
                        "consumer goods",
                        "materials",
                        "transportation"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-15",
                "original_text": "ACHV: Target Up On Longer Patent Life",
                "features": {
                    "keywords": [
                        "ACHV",
                        "Target",
                        "Up",
                        "Longer",
                        "Patent",
                        "Life"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-02",
                "original_text": "REFILE-After early COVID-19 response, Australia stuck in vaccine slow lane",
                "features": {
                    "keywords": [
                        "COVID-19",
                        "vaccine",
                        "slow lane"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false"
                }
            },
            {
                "time": "2021-06-16",
                "original_text": "CureVac Slumps After Confirming COVID Vaccine Candidate Only 48% Effective",
                "features": {
                    "keywords": [
                        "CureVac",
                        "Slumps",
                        "COVID",
                        "Vaccine",
                        "Candidate",
                        "48%",
                        "Effective"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}